search
Back to results

Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring

Primary Purpose

Scarring

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
dHACM
Craniectomy
Sponsored by
MiMedx Group, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Scarring

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults ages 18 or older.
  • Diagnosed with closed head trauma or cerebral infarction where decompressive craniectomy with durotomy is performed.
  • Willingness to comply with study procedures.
  • The patient's or legally authorized representative's (LAR's) ability to give full written consent.

Exclusion Criteria:

  • Prior surgery at the site
  • Participation in another ongoing trial
  • Open cranial wounds
  • Site exhibits clinical signs and symptoms of local infection.
  • Current diagnosis of cancer at the site
  • Prior radiation therapy treatment at the site.
  • Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
  • Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  • Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  • Currently taking medications which could affect graft incorporation (supervising physician's discretion).
  • Allergy to gentamicin sulfate and/or streptomycin sulfate

Sites / Locations

  • Boulder Neurological Associates
  • Chattanooga Center for Neurological Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Group 1 Control

Group 2 Treatment dHACM

Arm Description

Will receive only traditional craniectomy

Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.

Outcomes

Primary Outcome Measures

Degree of scarring between the galea and the dura, as assessed by the Ease of Dissection (EOD) Score and histological analysis upon reoperation in patients receiving craniectomy with durotomy.

Secondary Outcome Measures

Intra- and post-operative complications at reoperation, as assessed by occurrence of violation of the dura and/or violation of the parenchyma.
Post-operative complications at original and re-operation
Peri-operative measures at original and re-operation
Survival

Full Information

First Posted
November 21, 2013
Last Updated
August 22, 2018
Sponsor
MiMedx Group, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02033824
Brief Title
Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring
Official Title
A Multicenter Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane dHACM in Decompressive Craniectomy Patients to Reduce Postoperative Scarring
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
June 2018 (Actual)
Study Completion Date
June 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MiMedx Group, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effectiveness of dHACM in reducing scar tissue formation in craniectomy patients as well as facilitating reoperation and repair. Specifically this study compares craniectomy without dHACM application to craniectomy with placement of dHACM between the galea and dura over dural suture line and/or exposed parenchyma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Scarring

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1 Control
Arm Type
Other
Arm Description
Will receive only traditional craniectomy
Arm Title
Group 2 Treatment dHACM
Arm Type
Experimental
Arm Description
Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
Intervention Type
Other
Intervention Name(s)
dHACM
Other Intervention Name(s)
AmnioFix®
Intervention Description
A piece of dHACM placed over any dural defect or dural closure during craniectomy.
Intervention Type
Procedure
Intervention Name(s)
Craniectomy
Other Intervention Name(s)
Decompressive Craniectomy
Intervention Description
Removal of the skull flap followed by closure techniques per current SOC.
Primary Outcome Measure Information:
Title
Degree of scarring between the galea and the dura, as assessed by the Ease of Dissection (EOD) Score and histological analysis upon reoperation in patients receiving craniectomy with durotomy.
Time Frame
6 Months
Secondary Outcome Measure Information:
Title
Intra- and post-operative complications at reoperation, as assessed by occurrence of violation of the dura and/or violation of the parenchyma.
Time Frame
6 Months
Title
Post-operative complications at original and re-operation
Time Frame
6 Months
Title
Peri-operative measures at original and re-operation
Time Frame
6 Months
Title
Survival
Time Frame
6 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults ages 18 or older. Diagnosed with closed head trauma or cerebral infarction where decompressive craniectomy with durotomy is performed. Willingness to comply with study procedures. The patient's or legally authorized representative's (LAR's) ability to give full written consent. Exclusion Criteria: Prior surgery at the site Participation in another ongoing trial Open cranial wounds Site exhibits clinical signs and symptoms of local infection. Current diagnosis of cancer at the site Prior radiation therapy treatment at the site. Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment. Currently taking medications which could affect graft incorporation (supervising physician's discretion). Allergy to gentamicin sulfate and/or streptomycin sulfate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chris Clare, MD
Organizational Affiliation
MiMedx Group, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boulder Neurological Associates
City
Boulder
State/Province
Colorado
ZIP/Postal Code
80303
Country
United States
Facility Name
Chattanooga Center for Neurological Research
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring

We'll reach out to this number within 24 hrs